​FDA approves expansion of MDMA therapy

The Multidisciplinary Association for Psychedelic Studies has been granted approval for an expanded access programme of MDMA-assisted psychotherapy. The US Food and Drug Administration (FDA) approval means that patients will be eligible for access to MDMA treatments under investigation if those patients have a serious or life-threatening condition, if other therapies have not worked and if they do not qualify for participation in Phase 3 clinical trials.

Source: https://maps.org/news/media/8008-press-release-fda-agrees-to-expanded-access-program-for-mdma-assisted-psychotherapy-for-ptsd